Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities - PubMed (original) (raw)
. 1995 Dec 1;86(11):4250-6.
Affiliations
- PMID: 7492784
Free article
Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
G Tricot et al. Blood. 1995.
Free article
Abstract
Chromosomal abnormalities have major biologic and prognostic implications in leukemias. Cytogenetic information in typically hypoproliferative multiple myeloma (MM) is limited because of difficulties in obtaining analyzable metaphases. In this study, karyotypes and other known prognostic factors were analyzed in 155 newly diagnosed MM patients, entered on an intensive treatment program with two autotransplants. Complete remission (CR), event-free (EFS) and overall survival (OS) were analyzed using standard statistical methods. Abnormal cytogenetics were found in 39% of patients and were associated with a significantly lower CR rate (27% v 48%; P = .008). EFS and OS were inferior in patients with either partial or complete deletion of chromosome 13 or 11q abnormalities ("unfavorable" karyotype) when compared with the remaining patients (P < .001) who, as a group, had a similar prognosis irrespective of cytogenetic findings, ie, inevaluable, normal, or abnormal but without an "unfavorable" karyotype. The patients with abnormalities of both chromosomes 11 and 13 had a dismal prognosis with median EFS and OS of only 11 and 12 months, respectively. Significant associations were noted between an "unfavorable" karyotype and IgA isotype, elevated levels of beta-2 microglobulin (B2M, > or = 3 mg/L) and age > 60 years. On multivariate regression analysis, the absence of an "unfavorable" karyotype was the most significant variable associated with prolonged EFS and OS (P = .0001 and .0002, respectively). Other independent favorable variables were age less than 60 years, C-reactive protein (CRP) < or = 0.4 mg/dL and bone marrow plasmacytosis < or = 50% before treatment. On a multivariate analysis without cytogenetics, these same three standard parameters were identified as the only favorable variables. Patients not having all three standard favorable variables had a significantly lower CR rate (P = .03), EFS (P = .0001), and OS (P = .002) if an unfavorable karyotype was detected. We conclude that, in this program of uniformly treated MM patients, a poor prognosis was associated predominantly with abnormalities of chromosomes 11 and 13.
Similar articles
- Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.
Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S, Mattox S, Bracy D, Munshi N, Barlogie B. Tricot G, et al. J Clin Oncol. 1997 Jul;15(7):2659-66. doi: 10.1200/JCO.1997.15.7.2659. J Clin Oncol. 1997. PMID: 9215838 - Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
Königsberg R, Zojer N, Ackermann J, Krömer E, Kittler H, Fritz E, Kaufmann H, Nösslinger T, Riedl L, Gisslinger H, Jäger U, Simonitsch I, Heinz R, Ludwig H, Huber H, Drach J. Königsberg R, et al. J Clin Oncol. 2000 Feb;18(4):804-12. doi: 10.1200/JCO.2000.18.4.804. J Clin Oncol. 2000. PMID: 10673522 - Autotransplants in multiple myeloma: what have we learned?
Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D, Miller L, Cheson B, Crowley J, Barlogie B. Vesole DH, et al. Blood. 1996 Aug 1;88(3):838-47. Blood. 1996. PMID: 8704239 - Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.
Laï JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T. Laï JL, et al. Blood. 1995 May 1;85(9):2490-7. Blood. 1995. PMID: 7537117 Review. - The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Visani G, Bernasconi P, Boni M, Castoldi GL, Ciolli S, Clavio M, Cox MC, Cuneo A, Del Poeta G, Dini D, Falzetti D, Fanin R, Gobbi M, Isidori A, Leoni F, Liso V, Malagola M, Martinelli G, Mecucci C, Piccaluga PP, Petti MC, Rondelli R, Russo D, Sessarego M, Specchia G, Testoni N, Torelli G, Mandelli F, Tura S. Visani G, et al. Leukemia. 2001 Jun;15(6):903-9. doi: 10.1038/sj.leu.2402142. Leukemia. 2001. PMID: 11417475 Review.
Cited by
- Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity.
Kyrtsonis MC, Bartzis V, Papanikolaou X, Koulieris E, Georgiou G, Dimou M, Tzenou T, Panayiotidis P. Kyrtsonis MC, et al. Appl Clin Genet. 2010 Jul 28;3:41-51. doi: 10.2147/tacg.s7456. Print 2010. Appl Clin Genet. 2010. PMID: 23776351 Free PMC article. - Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression.
Chesi M, Stein CK, Garbitt VM, Sharik ME, Asmann YW, Bergsagel M, Riggs DL, Welsh SJ, Meermeier EW, Kumar SK, Braggio E, Bergsagel PL. Chesi M, et al. Blood Cancer Discov. 2020 Jul;1(1):68-81. doi: 10.1158/0008-5472.BCD-19-0068. Blood Cancer Discov. 2020. PMID: 32954360 Free PMC article. - NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.
van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy J, Tricot G. van Rhee F, et al. Blood. 2005 May 15;105(10):3939-44. doi: 10.1182/blood-2004-09-3707. Epub 2005 Jan 25. Blood. 2005. PMID: 15671442 Free PMC article. - Genomic complexity of multiple myeloma and its clinical implications.
Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Manier S, et al. Nat Rev Clin Oncol. 2017 Feb;14(2):100-113. doi: 10.1038/nrclinonc.2016.122. Epub 2016 Aug 17. Nat Rev Clin Oncol. 2017. PMID: 27531699 Review. - Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
Kiyota M, Kobayashi T, Fuchida S, Yamamoto-Sugitani M, Ohshiro M, Shimura Y, Mizutani S, Nagoshi H, Sasaki N, Nakayama R, Chinen Y, Sakamoto N, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Kuroda J, Taniwaki M. Kiyota M, et al. Int J Hematol. 2012 May;95(5):516-26. doi: 10.1007/s12185-012-1035-8. Epub 2012 Mar 17. Int J Hematol. 2012. PMID: 22426624
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous